Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linghui Pan has a total of 241 co-authors. Here are the top co-authors by number of shared publications:

  • Fei Lin

    Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Nanning, PR China

    19 shared publications
  • Ren Jing

    Guangxi Clinical Research Center for Anesthesiology, Guangxi Medical University Cancer Hospital

    16 shared publications
  • Huijun Dai

    Guangxi Clinical Research Center for Anesthesiology, Nanning 530021, PR China; Guangxi Engineering Research Center for Tissue & Organ Injury and Repair Medicine, Nanning 530021, PR China; Guangxi Health Commission Key Laboratory of Basic Science and Prevention of Perioperative Organ Disfunction, Nanning 530021, PR China; Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Nanning 530021, PR China

    14 shared publications
  • Maoyao Ling

    Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Liang Yu Rd No.50, Nanning, 530021, PR China

    11 shared publications
  • Sheng He

    The First Affiliated Hospital, Department of Anesthesiology, Hengyang Medical School, University of South China

    11 shared publications
  • Xiaoting Liao

    Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Liang Yu Rd No.50, Nanning, 530021, PR China

    11 shared publications

Latest Publications

  • Open Access

    Neurological adverse events associated with immune checkpoint inhibitors: a pharmacovigilance study based on the FAERS and JADER databases

    by Huilin Luo, Xianlong Xie, Shiran Qin, Linghui Pan, Liu Ye

    Background: Neurological adverse events (NAEs) have been reported during immune checkpoint inhibitor (ICI) therapy, but their reporting spectrum and onset patterns across drugs and pharmacovigilance databases remain incompletely characterized. Methods: We conducted a pharmacovigilance study of seven ICIs using the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) database. Primary drug–preferred term (PT) signals were evaluated using whole-database disproportionality analyses. An exploratory FAERS analysis compared PD-L1 with PD-1 inhibitors within study-defined tumor-indicator strata. Factors associated with NAE reporting were assessed in FAERS by univariate and multivariable logistic regression, and time-to-onset (TTO) was summarized using descriptive statistics and Weibull analyses. JADER cemiplimab data were summarized descriptively only because of sparse reporting. Results: The analysis included 3,915 NAE reports from FAERS and 2,929 from JADER. The heatmaps displayed 111 positive drug–PT pairs across 31 PTs in FAERS and 49 across 16 PTs in JADER. Myasthenia gravis showed a disproportionality signal for all seven ICIs in non-Japanese FAERS reports and for all six ICIs included in the JADER signal analysis; encephalitis-related terms and immune-mediated myositis also recurred, although drug-specific patterns varied. In FAERS, complete-case regression included 111,879 ICI-related reports with 2,887 NAEs. Age ≥65 years and ICI combination therapy were associated with higher adjusted odds of NAE reporting, whereas PD-L1 and CTLA-4 monotherapy were associated with lower adjusted reporting odds relative to PD-1 monotherapy. The stratified comparison showed lower myasthenia gravis reporting odds for PD-L1 than PD-1 in both strata; encephalitis confidence intervals included 1. Drug-level median TTOs ranged from 16 to 43 days in FAERS and from 16 to 32 days in JADER, with heterogeneous Weibull patterns across drugs and databases. Conclusion: ICI-associated neurological reports showed recurring neuromuscular and central nervous system signals, partial qualitative concordance between non-Japanese FAERS reports and JADER, and heterogeneous onset patterns across drugs. The observed reporting associations do not establish comparative clinical safety. Overall, these findings are descriptive and hypothesis-generating and warrant confirmation in studies with exposure denominators, clinically adjudicated diagnoses, and longitudinal follow-up.

  • Open Access

    Perioperative stress–inflammation–immunosuppression axis and tumor progression: mechanistic integration and anesthetic management strategies

    by Liu Ye, Honglei Shen, Jinyuan Lin, Shenglin Pei, Fei Lin, Xinyi Li, Enqiang Chang, Linghui Pan

    Perioperative stress is an unavoidable part of surgery and may be particularly relevant in patients with cancer. Surgical trauma activates two major stress pathways, the hypothalamic–pituitary–adrenal (HPA) axis and the sympathetic nervous system (SNS), leading to surges in stress hormones, inflammatory mediators, and a temporary reduction in anti-tumor immune function. This sequence can be described as a stress–inflammation–immunosuppression axis. Experimental studies suggest that excessive activation of this axis may support postoperative survival and spread of residual tumor cells, yet clinical outcome data remain inconsistent and often depend on cancer type, stage, and the overall perioperative care bundle. This review integrates mechanistic evidence on how perioperative stress and inflammation reshape immune surveillance, including effects on natural killer (NK) cells, cytotoxic T lymphocytes, myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and neutrophil extracellular traps (NETs). We also summarize how commonly used anesthetic drugs and techniques may modify stress signaling, inflammation, and immune function, and we critically appraise the current clinical evidence linking anesthetic management to biomarkers and oncologic outcomes. Finally, we propose an executable framework for individualized anesthetic planning that focuses on reducing stress peaks, limiting avoidable physiologic instability, supporting early recovery, and shortening the postoperative window of immunosuppression within enhanced recovery pathways.

  • Open Access

    Evolutionary patterns and research frontiers in ventilator-induced lung injury: a bibliometric analysis (2000–2024)

    by Yingliang Wu, Linghui Pan

    Background: Ventilator-induced lung injury (VILI) is a major complication of mechanical ventilation and contributes substantially to morbidity and mortality in critically ill patients. Despite extensive investigations into the pathophysiological mechanisms and preventive strategies of VILI, the global research landscape, collaborative networks, and emerging trends in this field have not been comprehensively characterized. This study aimed to systematically evaluate the development, research hotspots, and future directions of VILI research through bibliometric analysis. Methods: Publications related to VILI published between 2000 and 2024 were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric indicators, including annual publication output, citations, countries, institutions, authors, journals, and keywords, were analyzed. Visualization and network analyses were conducted using Bibliometrix (R package), VOSviewer, and CiteSpace to identify research collaborations, influential contributors, knowledge structures, and emerging research themes. Results: A total of 4,055 publications were included in the analysis. The annual number of publications (NP) and citations demonstrated a sustained upward trend, reflecting growing scientific interest in VILI. The United States was the leading contributor in terms of publication output, citations, and international collaborations. Harvard University and other major academic institutions played central roles in advancing the field. Highly cited studies primarily focused on lung-protective ventilation strategies, mechanical stress-induced inflammatory responses, and acute respiratory distress syndrome (ARDS). Keyword co-occurrence, burst detection, and thematic analyses revealed that inflammation, oxidative stress, NLRP3 inflammasome activation, epithelial and endothelial barrier dysfunction, mechanotransduction, and precision ventilation strategies have emerged as major research hotspots. Recent studies increasingly focus on molecular mechanisms and translational interventions aimed at reducing ventilator-associated lung damage. Conclusions: Research on VILI has expanded substantially over the past two decades, with increasing global collaboration and diversification of research themes. Current hotspots have shifted from clinical ventilation strategies toward mechanistic investigations involving inflammatory signaling pathways and cellular injury processes. These findings provide a comprehensive overview of the intellectual structure and developmental trajectory of VILI research and may help guide future basic, translational, and clinical investigations in this field.

  • Open Access

    Mechanical ventilation activates PERK/eIF2α and NOD1 pathways that contribute to NF-κB–driven inflammation in VILI

    by Maoyao Ling, Yalan Jiang, Umut Cakir, Kejian Lu, Xiaoting Liao, Guiting Yang, Liu Ji, Tingting Meng, Cuiyuan Huang, Liu Ye, et al.

    Ventilator-induced lung injury (VILI) is characterized by acute lung damage and NF-κB-driven cytokine production during mechanical ventilation. However, the upstream signals that initiate and exacerbate NF-κB-driven inflammation remain poorly understood. Although endoplasmic reticulum (ER) stress is implicated in VILI, how ER stress pathways interact with innate immune sensors to promote inflammation is incompletely defined. Here, we investigate the roles of NOD1 and the ER stress-responsive PERK/eIF2α pathway in a VILI mice model. C57BL/6 mice were subjected to high-tidal volume (HTV) ventilation for 4 h to establish an in vivo model of VILI. To investigate the role of NOD1 in VILI, Nod1-knockout (Nod1-KO) mice were generated. To further determine the involvement of the PERK pathway, wild-type and Nod1-KO mice were treated with PERK inhibitor GSK2606414 prior to HTV ventilation. Lung injury was evaluated using H&E staining, wet/dry ratio, and analysis of bronchoalveolar lavage fluid (BALF) for total protein concentration and inflammatory cell counts. Inflammatory cytokine levels were quantified by ELISA. Relative proteins expression was analyzed by immunoblotting and immunofluorescence. HTV ventilation induced lung histopathological damage, alveolar-capillary barrier dysfunction, and increased levels of IL-1β, IL-6, and TNF-α, along with upregulation of NOD1 and the ER stress marker GRP78. Genetic deletion of Nod1 attenuated lung injury and inflammatory cytokine release, associated with reduced GRP78 abundance and decreased NF-κB activation. In parallel, HTV increased phosphorylation of PERK and eIF2α, and pharmacological inhibition of PERK with GSK2606414 ameliorated lung injury and inflammation while suppressing NF-κB activation, without altering NOD1 protein abundance. Notably, combining NOD1 deficiency with PERK inhibition produced more pronounced protection against HTV-induced lung injury than either intervention alone, whereas the reduction of NF-κB readouts did not further deepen under the combined condition. HTV-induced inflammatory lung injury is associated with activation of both NOD1 and PERK/eIF2α signaling. Mechanistically, these pathways contribute to NF-κB-associated inflammatory responses and lung injury in VILI. Notably, the greater protection observed under combined NOD1 deficiency and PERK inhibition, despite a plateau in NF-κB readouts, suggests that additional injury mechanisms beyond NF-κB may also be involved.

  • Open Access

    Correction: Spatiotemporal regulation of ventilator lung injury resolution by TGF-β1+ regulatory b cells via macrophage vesicle-nanotherapeutics

    by Ren Jing, Xiaoting Liao, Jianlan Mo, Sheng He, Xianlong Xie, Zhaokun Hu, Linghui Pan

    Error in Figure 2A There was a mistake in Figure 2A as published. The images for the NTV1d and NTV10d groups have been replaced with correct images obtained from the same experimental conditions. The publisher apologizes for this mistake.In the published article, there was a mistake in Figure 2A. The images for the NTV1d and NTV10d groups were misused. Upon reexamination of the original experimental data, we found that incorrect representative images had been selected during figure assembly. These have now been replaced with the correct images obtained from the same experimental conditions. The corrected Figure 2A appears below.

  • Open Access

    HSP90AA1 inhibits the Jun/Fos pathway to rescue hepatocytes from cuproptosis during ischemia-reperfusion injury

    by Songling Xu, Yang Liu, Yingying Han, Maoyao Ling, Jipeng Nie, Linghui Pan

    Hepatic ischemia-reperfusion injury (HIRI), a frequent complication in procedures like hepatic lobectomy and organ transplantation, remains a significant clinical challenge despite advances in protective strategies. Cuproptosis, a copper-dependent form of cell death, has recently been linked to various inflammatory diseases, including HIRI. In this study, bioinformatic analyses were employed to identify differentially expressed core genes, and animal and cellular models of HIRI were established using C57BL/6 mice and AML12 cells to investigate the roles of HSP90AA1 and c-Jun/c-Fos-mediated cuproptosis in HIRI. Techniques including RT-qPCR, Western blotting, immunohistochemistry, immunofluorescence, and electron microscopy were used to assess cuproptosis, inflammation, and mitochondrial damage. Bioinformatic results indicated that HSP90AA1 and the Jun/Fos pathway are likely key targets in HIRI. Notably, increased cuproptosis and elevated HSP90AA1 expression in hepatocytes were observed both in vivo and in vitro following HIRI. Furthermore, HSP90AA1 overexpression significantly attenuated I/R-induced liver injury and cuproptosis by suppressing the Jun/Fos pathway. These findings reveal, for the first time, that HSP90AA1 can mitigate cuproptosis induced by HIRI via regulation of the Jun/Fos pathway, suggesting a potential novel therapeutic approach for HIRI.

  • Open Access

    Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinformatics and Experimental Approach

    by Yang Guiting, Shengfeng Zhang, Liu Ji, Chengmei Lv, Chen Zhao, Maoyao Ling, Xiaoting Liao, Linghui Pan

    BACKGROUND Acute lung injury (ALI) after liver transplantation (LT) is a critical complication negatively affecting transplant outcomes and patient survival. However, effective biomarkers for early diagnosis remain unidentified. This study aimed to identify hub biomarkers and signaling pathways involved in post-LT ALI through integrated bioinformatics and machine-learning analyses and to validate their diagnostic potential. MATERIAL AND METHODS Differential gene expression analysis identified 27 differentially expressed genes (DEGs). Functional enrichment analyses revealed significant involvement in cytokine-mediated signaling, particularly within the NF-kB and TNF pathways. Single-sample gene set enrichment analysis (ssGSEA) evaluated immune infiltration. Machine-learning algorithms identified crucial biomarkers for ALI prediction. Transcription factor-hub gene and competitive endogenous RNA (ceRNA) networks were constructed. Single-cell RNA sequencing (scRNA-seq) and enzyme-linked immunosorbent assay (ELISA) analyses validated biomarker expression patterns in relation to ALI. RESULTS Hub biomarkers identified included CXCL3, CD48, and IRAK3. ssGSEA revealed prominent macrophage and neutrophil infiltration associated with ALI. Machine-learning models confirmed CXCL3, CD48, and IRAK3 as reliable predictive biomarkers, which were incorporated into a robust diagnostic nomogram. scRNA-seq analysis showed cell-type-specific expression patterns for CXCL3, CD48, and IRAK3, with heterogeneous associations across datasets. ELISA validated significantly altered protein levels of CXCL3, CD48, and IRAK3 in post-transplant ALI cases compared with controls. CONCLUSIONS CXCL3, CD48, and IRAK3 are novel and promising diagnostic biomarkers for predicting post-LT ALI. These findings provide foundational insights that could support improved diagnosis, prevention strategies, and targeted therapeutic interventions, ultimately enhancing patient outcomes after liver transplantation.

  • Open Access

    Agrimoniin Alleviates Ferroptosis in Cold‐Stored DCD Liver Grafts Through Activation of the Nrf‐2 Pathway

    by Enqiang Chang, Xiaoting Liao, Guanghua Tao, Bijun Luo, Sheng He, Linghui Pan

    Liver grafts from donation‐after‐cardiac‐death (DCD) are vulnerable to ischemia–reperfusion injury, which compromises graft function after transplantation. Agrimoniin has been shown to possess antioxidant and anti‐inflammatory properties, making it a potential therapeutic agent for organ preservation. This study investigated whether supplementing agrimoniin to the University of Wisconsin (UW) cold storage solution protected liver grafts from DCD rats or cold preserved human liver cell lines (QSG‐7701 and HepG2). Agrimoniin supplementation significantly reduced oxidative damage, alleviated ferroptosis, and mitigated liver injury by activating the Nrf‐2 pathway, both in vivo and in vitro. These findings suggest that ferroptosis is a mediator in DCD liver injury, and agrimoniin, through its activation of the Nrf‐2 pathway, may be an effective therapeutic agent for enhancing liver graft preservation and improving outcomes in DCD liver transplantation.

  • Open Access

    Article title: Associations between paraben exposure and breast cancer risk: An integrative epidemiologic, network toxicology, multi-omics and experimental analysis

    by Liu Ji, Guiting Yang, Maoyao Ling, YanLin Xiao, Huajin Ou, YaLan Jiang, Xiaoting Liao, Jinyuan Lin, Linghui Pan


  • Open Access

    Integrated multi-omics analysis reveals PTM networks as key regulators of colorectal cancer progression and immune evasion

    by Guiting Yang, Liu Ji, Chengmei Lv, Chen Zhao, Riliang Ma, Ying Li, Yanyan Hu, Linghui Pan

    Background Colorectal cancer (CRC) is a leading cause of cancer mortality, with treatment resistance often driven by molecular heterogeneity and an immunosuppressive tumor microenvironment (TME). Post-translational modifications (PTMs) regulate key oncogenic processes, but their comprehensive role in CRC progression and immune evasion remains unexplored. Methods We integrated multi-omics data from bulk RNA-seq (GEO/TCGA, n = 1,783), single-cell transcriptomics (41,143 cells), and Mendelian randomization. Differential expression, GSVA, and machine learning (LASSO/SVM/Random Forest) were used to identify PTM-associated signatures. Functional validation included spatial transcriptomics, and immune profiling. Results Multi-omics analysis identified dysregulation in 80% of PTM pathways in CRC, with ubiquitination sustaining Wnt/β-catenin signaling and GALNT6-mediated glycosylation driving immune evasion through PD-L1 stabilization and CD8 + T cell exclusion. Single-cell analysis revealed GALNT6-specific enrichment in immune-excluded goblet cells (p < 0.05). Machine learning derived a 5-gene PTM Activity Signature (CCNB1IP1, GALNT6, NEDD4L, PSMD14, UBE2C) that distinguish between patients with diseases and those without (AUC = 1.00). GALNT6 was validated as a causal risk factor (OR = 1.10, 95%CI:1.01–1.18), with its inhibition synergizing with anti-PD-1 to enhance CD8 + T cell infiltration (p < 0.01). Conclusion This study establishes PTM networks as central regulators of CRC progression and immune resistance. The PTM-AS framework enables precision subtyping, while GALNT6 emerges as a novel therapeutic target for overcoming immunotherapy resistance.